publication . Article . 2016

Effect on Insulin-Stimulated Release of D-Chiro-Inositol-Containing Inositolphosphoglycan Mediator during Weight Loss in Obese Women with and without Polycystic Ovary Syndrome

Cheang, Kai I.; Sistrun, Sakita N.; Morel, Kelley S.; Nestler, John E.;
Open Access English
  • Published: 01 Sep 2016 Journal: International Journal of Endocrinology, volume 2,016 (issn: 1687-8337, eissn: 1687-8345, Copyright policy)
  • Publisher: Hindawi Publishing Corporation
Abstract
Background. A deficiency of D-chiro-inositol-inositolphosphoglycan mediator (DCI-IPG) may contribute to insulin resistance in polycystic ovary syndrome (PCOS). Whether the relationship between impaired DCI-IPG release and insulin resistance is specific to PCOS rather than obesity is unknown. We assessed insulin-released DCI-IPG and its relationship to insulin sensitivity at baseline and after weight loss in obese women with and without PCOS. Methods. Obese PCOS (n = 16) and normal (n = 15) women underwent 8 weeks of a hypocaloric diet. The Matsuda index, area under the curve DCI-IPG (AUCDCI-IPG), AUCinsulin, and AUCDCI-IPG/AUCinsulin were measured during a 2 hr ...
Subjects
mesheuropmc: endocrine system diseasesfemale genital diseases and pregnancy complications
free text keywords: Research Article, RC648-665, Diseases of the endocrine glands. Clinical endocrinology, Article Subject
Funded by
NIH| Insulin and the Polycystic Ovary Syndrome
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5K23HD049454-04
  • Funding stream: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT
,
NIH| PEPTIDES IN THE ADULT AND DEVELOPING VERTEBRATE NERVOUS SYSTEM
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1Z01HD000058-11
  • Funding stream: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT
27 references, page 1 of 2

Knochenhauer, E. S., Key, T. J., Kahsar-Miller, M., Waggoner, W., Boots, L. R., Azziz, R.. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. The Journal of Clinical Endocrinology & Metabolism . 1998; 83 (9): 3078-3082 [PubMed] [] [DOI]

Nestler, J. E., Jakubowicz, D. J., de Vargas, A. F., Brik, C., Quintero, N., Medina, F.. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. The Journal of Clinical Endocrinology & Metabolism . 1998; 83 (6): 2001-2005 [PubMed] [DOI]

Dunaif, A., Mandeli, J., Fluhr, H., Dobrjansky, A.. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome. Obstetrical and Gynecological Survey . 1988; 43 (11): 688-690 [] [DOI]

Romero, G., Larner, J.. Insulin mediators and the mechanism of insulin action. Advances in Pharmacology . 1993; 24: 21-50 [OpenAIRE] [PubMed] [] [DOI]

Asplin, I., Galasko, G., Larner, J.. Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proceedings of the National Academy of Sciences of the United States of America . 1993; 90 (13): 5924-5928 [OpenAIRE] [PubMed] [] [DOI]

Baillargeon, J.-P., Diamanti-Kandarakis, E., Ostlund, R. E., Apridonidze, T., Iuorno, M. J., Nestler, J. E.. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care . 2006; 29 (2): 300-305 [PubMed] [] [DOI]

Baillargeon, J.-P., Iuorno, M. J., Jakubowicz, D. J., Apridonidze, T., He, N., Nestler, J. E.. Metformin therapy increases insulin-stimulated release of d-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism . 2004; 89 (1): 242-249 [PubMed] [DOI]

Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., Allan, G.. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. The New England Journal of Medicine . 1999; 340 (17): 1314-1320 [PubMed] [] [DOI]

Iuorno, M. J., Jakubowicz, D. J., Baillargeon, J.-P.. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocrine Practice . 2002; 8 (6): 417-423 [PubMed] [DOI]

Laganà, A. S., Barbaro, L., Pizzo, A.. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with d-Chiro-Inositol. Archives of Gynecology and Obstetrics . 2015; 291 (5): 1181-1186 [PubMed] [] [DOI]

Gupta, A., Jakubowicz, D., Nestler, J. E.. Pioglitazone therapy increases insulin-stimulated release of d-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. Metabolic Syndrome and Related Disorders . 2016 [OpenAIRE] [DOI]

Baillargeon, J.-P., Iuorno, M. J., Apridonidze, T., Nestler, J. E.. Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome. Metabolic Syndrome and Related Disorders . 2010; 8 (2): 127-136 [OpenAIRE] [PubMed] [DOI]

Azziz, R., Carmina, E., Dewailly, D.. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. Journal of Clinical Endocrinology and Metabolism . 2006; 91 (11): 4237-4245 [PubMed] [] [DOI]

Guidelines for management of the obese and overweight. Obesity . 1998; 6 (2): 51S-179S [DOI]

Boulé, N. G., Weisnagel, S. J., Lakka, T. A.. Effects of exercise training on glucose homeostasis. Diabetes Care . 2005; 28 (1): 108-114 [PubMed] [] [DOI]

27 references, page 1 of 2
Abstract
Background. A deficiency of D-chiro-inositol-inositolphosphoglycan mediator (DCI-IPG) may contribute to insulin resistance in polycystic ovary syndrome (PCOS). Whether the relationship between impaired DCI-IPG release and insulin resistance is specific to PCOS rather than obesity is unknown. We assessed insulin-released DCI-IPG and its relationship to insulin sensitivity at baseline and after weight loss in obese women with and without PCOS. Methods. Obese PCOS (n = 16) and normal (n = 15) women underwent 8 weeks of a hypocaloric diet. The Matsuda index, area under the curve DCI-IPG (AUCDCI-IPG), AUCinsulin, and AUCDCI-IPG/AUCinsulin were measured during a 2 hr ...
Subjects
mesheuropmc: endocrine system diseasesfemale genital diseases and pregnancy complications
free text keywords: Research Article, RC648-665, Diseases of the endocrine glands. Clinical endocrinology, Article Subject
Funded by
NIH| Insulin and the Polycystic Ovary Syndrome
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5K23HD049454-04
  • Funding stream: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT
,
NIH| PEPTIDES IN THE ADULT AND DEVELOPING VERTEBRATE NERVOUS SYSTEM
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1Z01HD000058-11
  • Funding stream: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT
27 references, page 1 of 2

Knochenhauer, E. S., Key, T. J., Kahsar-Miller, M., Waggoner, W., Boots, L. R., Azziz, R.. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. The Journal of Clinical Endocrinology & Metabolism . 1998; 83 (9): 3078-3082 [PubMed] [] [DOI]

Nestler, J. E., Jakubowicz, D. J., de Vargas, A. F., Brik, C., Quintero, N., Medina, F.. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. The Journal of Clinical Endocrinology & Metabolism . 1998; 83 (6): 2001-2005 [PubMed] [DOI]

Dunaif, A., Mandeli, J., Fluhr, H., Dobrjansky, A.. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome. Obstetrical and Gynecological Survey . 1988; 43 (11): 688-690 [] [DOI]

Romero, G., Larner, J.. Insulin mediators and the mechanism of insulin action. Advances in Pharmacology . 1993; 24: 21-50 [OpenAIRE] [PubMed] [] [DOI]

Asplin, I., Galasko, G., Larner, J.. Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proceedings of the National Academy of Sciences of the United States of America . 1993; 90 (13): 5924-5928 [OpenAIRE] [PubMed] [] [DOI]

Baillargeon, J.-P., Diamanti-Kandarakis, E., Ostlund, R. E., Apridonidze, T., Iuorno, M. J., Nestler, J. E.. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care . 2006; 29 (2): 300-305 [PubMed] [] [DOI]

Baillargeon, J.-P., Iuorno, M. J., Jakubowicz, D. J., Apridonidze, T., He, N., Nestler, J. E.. Metformin therapy increases insulin-stimulated release of d-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism . 2004; 89 (1): 242-249 [PubMed] [DOI]

Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., Allan, G.. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. The New England Journal of Medicine . 1999; 340 (17): 1314-1320 [PubMed] [] [DOI]

Iuorno, M. J., Jakubowicz, D. J., Baillargeon, J.-P.. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocrine Practice . 2002; 8 (6): 417-423 [PubMed] [DOI]

Laganà, A. S., Barbaro, L., Pizzo, A.. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with d-Chiro-Inositol. Archives of Gynecology and Obstetrics . 2015; 291 (5): 1181-1186 [PubMed] [] [DOI]

Gupta, A., Jakubowicz, D., Nestler, J. E.. Pioglitazone therapy increases insulin-stimulated release of d-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. Metabolic Syndrome and Related Disorders . 2016 [OpenAIRE] [DOI]

Baillargeon, J.-P., Iuorno, M. J., Apridonidze, T., Nestler, J. E.. Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome. Metabolic Syndrome and Related Disorders . 2010; 8 (2): 127-136 [OpenAIRE] [PubMed] [DOI]

Azziz, R., Carmina, E., Dewailly, D.. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. Journal of Clinical Endocrinology and Metabolism . 2006; 91 (11): 4237-4245 [PubMed] [] [DOI]

Guidelines for management of the obese and overweight. Obesity . 1998; 6 (2): 51S-179S [DOI]

Boulé, N. G., Weisnagel, S. J., Lakka, T. A.. Effects of exercise training on glucose homeostasis. Diabetes Care . 2005; 28 (1): 108-114 [PubMed] [] [DOI]

27 references, page 1 of 2
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2016

Effect on Insulin-Stimulated Release of D-Chiro-Inositol-Containing Inositolphosphoglycan Mediator during Weight Loss in Obese Women with and without Polycystic Ovary Syndrome

Cheang, Kai I.; Sistrun, Sakita N.; Morel, Kelley S.; Nestler, John E.;